How endocrine tumors develop resistance to alkylating chemotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective multicenter study enrolling about 94 patients at Swedish endocrine cancer centers to track genetic changes after alkylating chemotherapy. Participants are divided into two groups: those about to start alkylating therapy and those with disease progression after prior alkylating treatment. The study collects tumor tissue biopsies, blood samples for circulating tumor DNA, and imaging to look for the emergence of high tumor mutational burden and mismatch repair–related mutations. Genomic sequencing will be used to quantify hypermutation and correlate tissue findings with non-invasive measures over time.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Informed consent
* Age ≥18 years
* Histopathology confirmed endocrine neoplasm
* Treatment with alkylating chemotherapy: Arm A; about to start alkylating chemotherapy, or Arm B; at disease progression or recurrence with previous alkylating chemotherapy treatment.

Exclusion Criteria:

* If planned tissue biopsy: risk factors for biopsy-related complications accordingly to local investigator, including coagulation disorder
* Long term treatment with anticoagulant that cannot be temporarily paused without unacceptable risk
* Pregnancy

Where it's running

• Akademiska Sjukhuset
  Uppsala, Sweden Recruiting

Study contacts

• Principal investigator: Joakim Crona, MD PhD — Uppsala University Hospital
• Study coordinator: Lovisa Falkman, MD
• Email: lovisa.falkman@uu.se
• Phone: +46186110000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• External validation of the TB-NET score in advanced well‑differentiated neuroendocrine tumors

  This study tests whether the TB-NET score can predict progression-free survival in adults with advanced well-differentiated gastroenteropancreatic neuroendocrine tumors or lung carcinoids who have received systemic therapy.

  Recruiting at 11 sites Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz · Boston, Massachusetts and 10 other locations · NCT07903532

• Ultralow-dose PET imaging of somatostatin receptor 2 (SSTR2) uptake

  This study will test whether an ultralow-dose 68Ga-Dotatate PET scan on a high-sensitivity scanner can detect SSTR2 uptake in adults with and without neuroendocrine tumors.

  Recruiting Phase 2 Nuclear Imaging Institute · Englewood, New Jersey · NCT07284589

• Quality of life after surgery for neuroendocrine tumors

  This study looks at how surgery for neuroendocrine tumors affects the quality of life for patients to help improve their care after the operation.

  Recruiting Sunnybrook Health Sciences Centre · Toronto, Ontario · NCT06981455

• Removal of the primary small-intestine neuroendocrine tumor versus systemic therapy alone

  This project tries to see if removing the main small-intestine neuroendocrine tumor helps people with incurable metastatic disease live longer or avoid future problems, compared with treating them with systemic therapy alone.

  Recruiting Insel Gruppe AG, University Hospital Bern · Bern · NCT06787014

• Using advanced imaging to detect small bowel neuroendocrine tumors

  This study is testing a new imaging method to see if it can better find small bowel neuroendocrine tumors in patients, helping doctors decide on the best treatment.

  Recruiting European Institute of Oncology · Milan · NCT06773624

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.